What Are the Challenges Associated with ATP Binding Site Inhibitors?
While ATP binding site inhibitors have shown promise, they also face several challenges:
1. Selectivity: Many proteins have similar ATP binding sites, making it difficult to design inhibitors that selectively target cancerous proteins without affecting normal cellular functions.
2. Resistance: Cancer cells can develop resistance to ATP binding site inhibitors through mutations in the target protein or activation of alternative pathways. Overcoming this resistance is a significant area of ongoing research.
3. Toxicity: Inhibitors can sometimes cause off-target effects, leading to toxicity and adverse side effects. Balancing efficacy and safety is crucial in the development of these drugs.
